Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
Canada
· Delayed Price · Currency is CAD 5.38
+0.05 (0.94%)
May 13, 2025, 10:41 AM EDT
Eupraxia Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Cash & Equivalents | 27.45 | 33.1 | 19.34 | 18.26 | 16.51 | 0.12 | Upgrade
|
| Short-Term Investments | - | - | - | - | 7.12 | - | Upgrade
|
| Cash & Short-Term Investments | 27.45 | 33.1 | 19.34 | 18.26 | 23.63 | 0.12 | Upgrade
|
| Cash Growth | -23.54% | 71.14% | 5.91% | -22.70% | 19954.27% | -86.78% | Upgrade
|
| Other Receivables | 0.24 | 0.23 | 0.19 | 0.09 | 0.34 | 0.49 | Upgrade
|
| Receivables | 0.24 | 0.23 | 0.19 | 0.09 | 0.34 | 0.49 | Upgrade
|
| Prepaid Expenses | 0.91 | 1.11 | 0.27 | 0.24 | 0.21 | 0.29 | Upgrade
|
| Total Current Assets | 28.61 | 34.44 | 19.8 | 18.59 | 24.18 | 0.89 | Upgrade
|
| Property, Plant & Equipment | 0.55 | 0.42 | 0.46 | 0.53 | 0.47 | 0.25 | Upgrade
|
| Other Long-Term Assets | 0.08 | 0.08 | 0.01 | 0 | 0.02 | - | Upgrade
|
| Total Assets | 29.23 | 34.94 | 20.27 | 19.12 | 24.67 | 1.14 | Upgrade
|
| Accrued Expenses | - | 3.01 | 3.87 | 2.91 | 1.67 | 2.38 | Upgrade
|
| Short-Term Debt | - | - | - | - | - | 9.82 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | 10.4 | 0.08 | 0.08 | - | Upgrade
|
| Current Portion of Leases | 0.05 | 0.07 | 0.05 | 0.05 | 0.05 | 0.04 | Upgrade
|
| Current Income Taxes Payable | - | - | 0.04 | - | - | - | Upgrade
|
| Other Current Liabilities | - | 0.02 | 5.02 | 0.02 | 0 | 5.44 | Upgrade
|
| Total Current Liabilities | 2.2 | 3.1 | 19.37 | 3.06 | 1.79 | 17.69 | Upgrade
|
| Long-Term Debt | - | - | - | 8.8 | 7.66 | - | Upgrade
|
| Long-Term Leases | - | - | - | 0.05 | 0.11 | 0.16 | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | - | 0.3 | Upgrade
|
| Total Liabilities | 2.2 | 3.1 | 19.37 | 11.91 | 9.56 | 18.14 | Upgrade
|
| Common Stock | 116.84 | 116.36 | 92.91 | 71 | 61.36 | 18.68 | Upgrade
|
| Additional Paid-In Capital | 21.95 | 20.5 | 17.51 | 16.85 | - | 4.86 | Upgrade
|
| Retained Earnings | -137.77 | -131 | -105.5 | -77.28 | -58.68 | -40.18 | Upgrade
|
| Comprehensive Income & Other | -4.12 | -4.16 | -2.71 | -2.79 | 13.09 | - | Upgrade
|
| Total Common Equity | -3.1 | 1.7 | 2.22 | 7.79 | 15.77 | -16.65 | Upgrade
|
| Minority Interest | -1.57 | -1.57 | -1.32 | -0.58 | -0.66 | -0.36 | Upgrade
|
| Shareholders' Equity | 27.03 | 31.84 | 0.89 | 7.21 | 15.11 | -17 | Upgrade
|
| Total Liabilities & Equity | 29.23 | 34.94 | 20.27 | 19.12 | 24.67 | 1.14 | Upgrade
|
| Total Debt | 0.05 | 0.07 | 10.45 | 8.99 | 7.9 | 10.02 | Upgrade
|
| Net Cash (Debt) | 27.4 | 33.03 | 8.89 | 9.28 | 15.73 | -9.9 | Upgrade
|
| Net Cash Growth | 3.99% | 271.55% | -4.18% | -41.03% | - | - | Upgrade
|
| Net Cash Per Share | 0.77 | 0.97 | 0.37 | 0.48 | 1.27 | -1.62 | Upgrade
|
| Filing Date Shares Outstanding | 35.69 | 35.85 | 35.62 | 27.36 | 14.24 | 12.87 | Upgrade
|
| Total Common Shares Outstanding | 35.69 | 35.64 | 27.28 | 21.59 | 14.24 | 6.18 | Upgrade
|
| Working Capital | 26.41 | 31.33 | 0.43 | 15.53 | 22.39 | -16.8 | Upgrade
|
| Book Value Per Share | -0.09 | 0.05 | 0.08 | 0.36 | 1.11 | -2.69 | Upgrade
|
| Tangible Book Value | -3.1 | 1.7 | 2.22 | 7.79 | 15.77 | -16.65 | Upgrade
|
| Tangible Book Value Per Share | -0.09 | 0.05 | 0.08 | 0.36 | 1.11 | -2.69 | Upgrade
|
| Buildings | - | - | - | - | 0.07 | 0.07 | Upgrade
|
| Machinery | - | 0.7 | 0.68 | 0.61 | 0.1 | 0.07 | Upgrade
|
| Leasehold Improvements | - | 0.12 | 0.13 | 0.13 | 0.13 | 0.08 | Upgrade
|
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.